Omega-3-acid ethyl esters(Trygg Pharma AS)

ORLANDO, Fla., March 7, 2025 /PRNewswire/ -- The 2025 American Academy of Dermatology Annual Meeting will take place March 7-11 in Orlando. The meeting will feature nearly 300 educational sessions with more than 1,700 speakers discussing the latest research on skin, hair, and nails, including topics on how diet and lifestyle can transform skin health, eczema management, and insights into aging skin. A New Era in Skin Health: GLP-1 Medications Your skin is often a window to your overall health, including underlying inflammatory and metabolic conditions. New treatments, like GLP-1 medications commonly used for weight loss, can help manage obesity, reduce inflammation, and improve skin conditions, highlighting how board-certified dermatologists are advancing personalized care. Inflammation and Skin Conditions Are Linked: Obesity often causes inflammation that can worsen or trigger skin conditions like psoriasis, eczema, and hidradenitis suppurativa, a chronic disease that causes painful lumps to form under the skin. GLP-1 Medications and Your Skin: While originally developed to treat diabetes and, more recently, promote weight loss, GLP-1 medications can reduce inflammation caused by obesity and improve certain skin conditions. A New Era of Dermatology: Treating conditions like obesity can bring about a healthier 'you' and help skin treatments work better, leading to more complete care. Lindsey Bordone, MD, FAAD, an assistant professor of dermatology at Columbia University Department of Dermatology, can discuss the connection between obesity and skin health, and how addressing your overall health can benefit your skin and well-being. The Role of Diet in Managing Eczema Many people believe that food is the root cause of atopic dermatitis, commonly known as eczema, which can result in dry, itchy skin. However, the relationship between diet and this common skin condition is more complex than it seems. New research is shedding light on how diet influences eczema – which affects nearly one in ten Americans – and empowers patients to make more informed choices. Cutting Foods Isn't a Cure-All: For most patients, simply eliminating certain foods doesn't significantly improve eczema symptoms, despite common misconceptions. The Role of a Healthy Diet: Emphasizing overall healthy eating and avoiding allergens can still play an important role in managing eczema. Early Allergen Introduction: Introducing allergenic foods early in life may help build tolerance, offering a powerful shift in how people manage their eczema. Peter A. Lio, MD, FAAD, a clinical assistant professor of dermatology at Northwestern Medicine in Chicago, can provide evidence-based strategies for managing eczema through diet and lifestyle. How Diet Can Enhance the Effectiveness of Skin Treatments The foods you eat play a vital role in how well medications work for skin conditions and can even help to minimize possible side effects. By making thoughtful dietary choices, you can support your skin health, maximize the effectiveness of treatments for skin disease, and improve your overall health. Optimize Treatment with Nutrition: The Mediterranean diet, which encourages people to eat plant-based foods, and omega-3 fats, can help make biologic treatments for psoriasis more effective, while also reducing heart disease risks associated with this common skin condition. Support Immunotherapy with Fiber: For advanced melanoma, the deadliest form of skin cancer, a diet rich in fiber from fruits, vegetables, and whole grains enhances the effectiveness of immunotherapy, a cancer treatment that uses the patient's own immune system to fight the disease. At the same time, patients should avoid probiotic supplements, which can make treatments less effective. Complement Therapy with Supplements: For those who suffer from acne, omega-3 supplements improve the absorption of isotretinoin, a common acne medication, and minimize its side effects. Steven Daveluy, MD, FAAD, an associate professor of dermatology at Wayne State University in Dearborn, Michigan, details how your diet can work alongside your treatment plan for healthier skin and a healthier you. Understanding Itch: A Window into Aging Skin Itch is the most common symptom for which patients over 50 visit a dermatologist. Importantly, recent scientific breakthroughs and treatment innovations are revolutionizing dermatologists' understanding and management of this condition. More than a symptom, itch offers valuable insights into how the immune system, nervous system, and skin barrier – the outermost layer of skin that serves as a protective shield for the body – change as we age. Increasingly More Common and Severe: Itch becomes more common and severe with age, significantly impacting quality of life, including sleep, daily activities, and our ability to care for others. Complicated Causes in Older Adults: Diagnosing the cause of itch in older adults is harder because visual signs and lab clues are less definitive. This can result in undertreatment. Evolving Treatments: While there are no FDA-approved medications specifically for itch, dermatologists have a variety of treatments at hand to address its effects, including moisturizers as well as topical ointments, phototherapy, biologics – which target diseases throughout your body and neurologic treatments like nerve creams and oral medications. Daniel C. Butler, MD, FAAD, an assistant dean and an associate professor of dermatology at University of Arizona College of Medicine in Tucson, can discuss the types of personalized treatment options dermatologists recommend for patients who struggle with persistent itch. If you have questions about a skin, hair, or nail condition, consult a board-certified dermatologist to ensure you receive trusted, expert guidance tailored to your needs. About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest, and YouTube, and @AADskin1 on Instagram. SOURCE American Academy of Dermatology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN FRANCISCO--( BUSINESS WIRE )--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases, today announced additions to its management team and board of directors. “Momentum continues to build at Marea as we advance our lead program, MAR001, through clinical development,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. “We are pleased to welcome Rebecca and Max to our leadership team and Robert to our board of directors. Their collective experience and expertise will be important as Marea enters its next phase of growth.” Rebecca Juliano, Ph.D., Appointed as Chief Development Officer Dr. Juliano has been in lipid-related research for more than 25 years and brings to Marea industry leadership experience across clinical program design, execution and communication. Most recently, Dr. Juliano served as chief operating officer at a stealth biotech startup, where she shaped teams and clinical programs for cardiovascular and rare disease indications. Prior to that, she led the clinical and related teams at Amarin Pharma, which were responsible for the cardiovascular outcomes trial REDUCE-IT, which received global approvals, led to changes in at least 15 global clinical guidelines, and received numerous accolades such as being named a top clinical trial by AHA, ACC and NEJM. Dr. Juliano began her industry career at Reliant Pharmaceuticals with the launch of Lovaza, and she has served multiple leadership and transitional consulting roles across her career. Prior to joining industry, Dr. Juliano was an AHA fellow at Weill Cornell Medical Center. She holds a Ph.D. from Columbia University and earned a B.S. in chemistry from the University of California, Santa Cruz. Max Zeiberg Appointed as Senior Vice President, Corporate Development Mr. Zeiberg most recently served as vice president, business development at Sana Biotechnology and at Graphite Bio, where he led partnering, strategic planning, and contributed to Graphite's Series B and IPO financings. Prior to that, Mr. Zeiberg held roles of increasing responsibility on the corporate development team at Gilead Sciences, culminating as head of virology partnering and M&A. During his time at Gilead, he successfully led numerous strategic transactions to build the company’s pipeline. Mr. Zeiberg began his career advising life science companies on commercial strategy and pipeline prioritization as a management consultant with ZS Associates. Mr. Zeiberg holds a B.S. in biomedical engineering from Columbia University and an MBA from the Kellogg School of Management at Northwestern University. Robert A. Harrington, M.D., Appointed to Board of Directors Dr. Harrington is a cardiologist and serves as the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. His research areas of focus include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, and trying to better understand and improve upon the methodology of clinical research, including the use of technologies to facilitate the conduct of clinical trials. Dr. Harrington was the Arthur L. Bloomfield Professor and chair of the Department of Medicine at Stanford University for more than 10 years. He previously served as the Richard Stack Distinguished Professor and the director of the Duke Clinical Research Institute at Duke University, where he completed his fellowship in general and interventional cardiology. Dr. Harrington holds a Bachelor’s degree in English from the College of the Holy Cross and an M.D. from Tufts University School of Medicine. He served as chief resident during his residency in internal medicine at the University of Massachusetts Medical Center in Worcester. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X .